Figure 2
![Figure 2. Platelet responses during the treatment period in all placebo- and romiplostim-treated patients and in patients by age cohort. (A) Median (25th [Q1] and 75th [Q3] percentiles) number of weeks that platelet counts were 50 × 109/L or greater during the treatment period. Platelet counts within 4 weeks of administration of rescue medication were excluded from these analyses. (B) Percent of patients who had platelet counts of 50 × 109/L or greater for 2 consecutive weeks in the absence of rescue medication. (C) Percent of patients who had an increase in platelet counts of 20 × 109/L or greater above baseline for 2 consecutive weeks in the absence of rescue medication.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/1/10.1182_blood-2010-10-313908/4/zh89991172640002.jpeg?Expires=1723418354&Signature=pU0RxWRAEP2ZGSWXfa0tBDVzYikiuhiHZTnVDh9CzCkqpTJ8Azs~w1cNGcFIgBjJCAWwkJpT~fpRC1Xi2qk2DZoyDx-zRHL1j~pr8pnq9KJClQjw9Ydk9bt90HNwjZ3bglM0d32WPQLVVQklm4J~NmVUvBOEy1jgQpUG~wCRREKPRuwMKRBcDM9~oWXnQO8kx9JsexqdMTKdJkHf75S8wY8kxSVqE4kn24G7WFHQvGqBdw44nuV9E7sq7NKy1VZ2h65StGc7IiLXvsLP7BSDN9uV47c9Se5soQsYFn~AAFpv5zAm-HfXaba20j4QjM5uZLBkFSBIoNAnAXxdhNWbJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Platelet responses during the treatment period in all placebo- and romiplostim-treated patients and in patients by age cohort. (A) Median (25th [Q1] and 75th [Q3] percentiles) number of weeks that platelet counts were 50 × 109/L or greater during the treatment period. Platelet counts within 4 weeks of administration of rescue medication were excluded from these analyses. (B) Percent of patients who had platelet counts of 50 × 109/L or greater for 2 consecutive weeks in the absence of rescue medication. (C) Percent of patients who had an increase in platelet counts of 20 × 109/L or greater above baseline for 2 consecutive weeks in the absence of rescue medication.
